These findings collectively establish that GOX-mediated catalytic therapy can potentiate immunotherapy by: (1) remodeling the immunosuppressive TME, (2) inducing ICD to enhance tumor immunogenicity, and (3) promoting antigen presentation and T cell activation. The gene discussed is HAO1; the disease is neoplasm.